Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with
alcohol dependence and comorbid schizophrenia spectrum disorders.
- 1: Relative to placebo, acamprosate will significantly increase cumulative days of
abstinence in recently detoxified alcohol dependent schizophrenia patients measured by
Timeline Follow-Back (TLFB) method.
- 2: Acamprosate will have no significant effect on the psychotic symptoms in
schizophrenia patients with alcohol dependence as measured by the Positive and Negative
Syndrome Scale (PANSS).